T1	p 173 238	patients with chronic heart failure after myocardial infarction .
T2	p 373 409	patients with heart failure ( HF ) .
T3	p 575 600	patients with class II to
T4	p 604 630	HF and ejection fraction <
T5	p 757 763	Living
T6	p 769 771	HF
T7	p 833 837	, 23
T8	p 897 906	financial
T9	p 915 916	.
T10	p 1132 1159	myoblast-treated patients :
T11	p 1442 1448	Living
T12	p 1481 1551	HF patients with chronic postinfarction cardiomyopathy , transcatheter
T13	p 1849 1880	HF patients with postinfarction
T14	i 136 160	implantation by catheter
T15	i 312 341	transcatheter intramyocardial
T16	i 360 369	myoblasts
T17	i 418 424	MARVEL
T18	i 441 459	placebo-controlled
T19	i 469 481	image-guided
T20	i 484 550	catheter-based intramyocardial injection of placebo or myoblasts (
T21	i 738 742	test
T22	i 990 1003	8 ( placebo )
T23	i 1100 1110	amiodarone
T24	i 1160 1173	1 ( placebo )
T25	i 1304 1313	?6-minute
T26	i 1354 1361	placebo
T27	i 1521 1535	cardiomyopathy
T28	i 1538 1551	transcatheter
T29	i 1570 1579	myoblasts
T30	i 1718 1726	myoblast
T31	i 1822 1830	myoblast
T32	i 1881 1895	cardiomyopathy
T33	o 81 114	safety and cardiovascular effects
T34	o 152 160	catheter
T35	o 277 283	safety
T36	o 620 628	fraction
T37	o 662 708	frequency of serious adverse events ( safety )
T38	o 713 788	changes in 6-minute walk test and Minnesota Living With HF score ( efficacy
T39	o 947 964	numbers of events
T40	o 1053 1085	deaths . Ventricular tachycardia
T41	o 1245 1264	functional capacity
T42	o 1304 1323	?6-minute walk test
T43	o 1429 1465	in Minnesota Living With HF scores .
T44	o 1687 1698	tachycardia